There is an increasing use of monoclonal antibodies in the treatment of haematological malignancies. Alemtuzumab (Campath-1H; Ilex Pharmaceuticals, San Antonio, TX, USA) is a monoclonal antibody reactive with the CD52 antigen used as first and second line therapy for two types of lymphoproliferative disorders: chronic lymphocytic leukaemia (CLL), and T-cell lymphomas [both peripheral (PTCL) and...

Neurotropic recombinant strain of Mouse Hepatitis Virus, RSA59, induces meningo-encephalitis, myelitis and demyelination following intracranial inoculation. RSA59 induced neuropathology is partially caused by activation of CNS resident microglia, as demonstrated by changes in cellular morphology and increased expression of a microglia/macrophage specific calcium ion binding factor, Iba1. Affyme...

Peripheral T-cell lymphomas (PTCLs) are heterogeneous and uncommon malignancies featuring an aggressive clinical course and a mostly poor outcome with current treatment strategies [1]. Recent developments using genome-wide molecular profiling methods have provided novel insights into their pathobiology and identified new markers with diagnostic, prognostic and/or therapeutic implications.Cell l...

Acute leukemia is a heterogeneous group of malignancies with varying clinical, morphologic, immonophenotypic, genetic and molecular characteristics. Despite the increasing importance of molecular and genetic features in the sub-classification of acute leukemias, morphologic and immunophenotypic analysis remains the main modality to diagnose acute leukemia for initial evaluation and providing a ...

T he article by Matiello et al 1 regarding a relapse of neuromyelitis optica (NMO) after autologous hematopoietic stem cell transplantation highlights the need to further understand the role of the immune system in this disease. Immunosuppressive therapeutics targeting B and T cells are used to prevent disabling relapses in NMO. Rituximab is a monoclonal antiCD20 antibody that is reported to be...

BACKGROUND Standard therapy for severe, immune mediated, ocular inflammation has significant side effects, and may fail to control the disease. T cell directed monoclonal antibody (mAb) therapy can provide long term remission of inflammatory disease in experimental models. The Campath-1H mAb was administered to patients with severe, refractory, ocular inflammation. METHODS 10 patients with se...

Alemtuzumab is a humanized chimeric monoclonal antibody targeting CD52. Although this agent already has an important role in the treatment of chronic lymphocytic leukemia (CLL), many of its uses are still being defined. Early trials showed alemtuzumab's value in refractory disease and helped to define its excellent activity in the bone marrow, spleen and 17p deleted patients. The CAM307 trial h...

Introduction. Alemtuzumab is a humanized monoclonal antibody against the CD52 antigen. It highly efficacious drug for treatment of relapsing remitting multiple sclerosis (MS). The protocol consists in 2 cycles: 12mg/day i.v. infusions 5 consecutive days and after one-year 3 days. To our knowledge, there single case series literature detailing MS remission cycle Alemtuzumab. Here, we report simi...

Bone marrow aspirates from 306 patients with multiple myeloma were analyzed by flow cytometric immunophenotyping. The plasma cells (PCs) were identified by their characteristic light scatter distribution and reactivity patterns to CD138, CD38, and CD45. Monoclonality was confirmed by immunoglobulin light chain analysis. The immunophenotypic profile of the PCs was determined with a panel of anti...

Bortezomib has been known as the most promising anti-cancer drug for multiple myeloma (MM). However, recent studies reported that not all MM patients respond to bortezomib. To overcome such a stumbling-block, studies are needed to clarify the mechanisms of bortezomib resistance. In this study, we established a bortezomib-resistant cell line (U266/velR), and explored its biological characteristi...